|
| Status |
Public on Mar 21, 2016 |
| Title |
ER ChIP-seq of Androstenedione treated Letrozole Resistant Breast Cancer Cell line |
| Organism |
Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
Acquired resistance to aromatase inhibitor (AI) therapy is a major clinical problem in the treatment of breast cancer. The detailed mechanisms of how tumour cells develop this resistance remain unclear. Here estrogen receptor ChIPseq analysis identifies adaptations of the ER in response to prolonged letrozole treatment.
|
| |
|
| Overall design |
Let-R cells were treated with either Androstenedione or vehicle and immunoprecipitated with anti-ER
|
| |
|
| Contributor(s) |
Young L, Fagan A, McBryan J, Vareslija D |
| Citation(s) |
26763249 |
| |
| Submission date |
Jan 31, 2014 |
| Last update date |
May 15, 2019 |
| Contact name |
Leonie Young |
| Organization name |
Royal College of Surgeons, Ireland
|
| Department |
Surgery
|
| Lab |
Endocrine Oncology Research Group
|
| Street address |
York Street
|
| City |
Dublin |
| ZIP/Postal code |
Dublin 2 |
| Country |
Ireland |
| |
|
| Platforms (3) |
| GPL9115 |
Illumina Genome Analyzer II (Homo sapiens) |
| GPL10999 |
Illumina Genome Analyzer IIx (Homo sapiens) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
| Samples (8)
|
|
| Relations |
| BioProject |
PRJNA237102 |
| SRA |
SRP036128 |
Less...
More...